High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Rauser, Sandra ^a   Langer, Rupert ^b   Tschernitz, Sebastian ^a   Gais, Peter ^a   Jütting, Uta ^a   Feith, Marcus ^c   Höfler, Heinz ^a,b   Walch, Axel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CD45 ANTIGEN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MALE; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; BIOSYNTHESIS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD45; ANTIGENS, CD8; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 78049363064     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-608     Document Type: Article

References (32)

1. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006, 13(1):12-30. 10.1245/ASO.2005.12.025, 16378161.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20. 10.1056/NEJMoa055531, 16822992.
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8(3):226-234. 10.1016/S1470-2045(07)70039-6, 17329193.
5. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg 2007, 246(4):624-628. discussion 628-631, 10.1097/SLA.0b013e318155a7d1, 17893499.
6. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum Immunol 2008, 69(4-5):241-249. 10.1016/j.humimm.2008.02.005, 18486758.
7. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest 2006, 86(3):231-245. 10.1038/labinvest.3700389, 16446705.
8. Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008, 99(10):1704-1711. 10.1038/sj.bjc.6604738, 2584941, 18941457.
9. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27(35):5944-5951. 10.1200/JCO.2008.19.6147, 19858404.
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964. 10.1126/science.1129139, 17008531.
11. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353(25):2654-2666. 10.1056/NEJMoa051424, 16371631.
12. de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, Nijman HW. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 2009, 114(1):105-110. 10.1016/j.ygyno.2009.03.022, 19411095.
13. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007, 67(1):354-361. 10.1158/0008-5472.CAN-06-3388, 17210718.
14. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102(51):18538-18543. 10.1073/pnas.0509182102, 1311741, 16344461.
15. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348(3):203-213. 10.1056/NEJMoa020177, 12529460.
16. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007, 104(10):3967-3972. 10.1073/pnas.0611618104, 1820692, 17360461.
17. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25(18):2586-2593. 10.1200/JCO.2006.09.4565, 17577038.
18. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007, 25(7):869-875. 10.1200/JCO.2006.08.9755, 17327608.
19. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007, 67(5):1883-1886. 10.1158/0008-5472.CAN-06-4806, 17332313.
20. Werner M, Flejou JF, Hainaut P, Höfler H, Lambert R, Keller G, Stein HJ. Adenocarcinoma of the oesophagus. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Digestive System 2000, 20-26. Lyon: IARC Press, Hamilton SR, Aaltonen LA.
21. Brugal G, Garbay C, Giroud F, Adelh D. A double scanning microphotometer for image analysis: hardware, software and biomedical applications. J Histochem Cytochem 1979, 27(1):144-152.
22. Mueller J, Werner M, Siewert JR. Malignant progression in Barrett's esophagus: pathology and molecular biology. Recent Results Cancer Res 2000, 155:29-41.
23. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
24. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3(11):991-998. 10.1038/ni1102-991, 12407406.
25. Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Shichinohe T, Hirano S, Shinohara T, Itoh T, Kondo S. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008, 98(7):1258-1263. 10.1038/sj.bjc.6604294, 2359642, 18349839.
26. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003, 63(7):1555-1559.
27. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Correlation between the lymphocytic infiltration of tumors and the proliferative activity of cancer cells from surgically treated esophageal carcinoma. Oncology 1997, 54(4):311-317. 10.1159/000227709, 9216856.
28. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61(10):3932-3936.
29. Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, Went P, Oertli D. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol 2010, 36(7):670-677.
30. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27(2):186-192. 10.1200/JCO.2008.18.7229, 19064967.
31. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997, 337(17):1188-1194. 10.1056/NEJM199710233371702, 9337377.
32. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763. 10.1146/annurev.immunol.22.012703.104702, 15032595.